Suzhou, April 21, 2024-Kintor
Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage
biotechnology company developing innovative small molecules and biological
therapeutics, announced that the China phase II clinical trial (the “Phase II
Clinical Trial”) of its in-house developed first-in-class androgen receptor
(“AR”) proteolysis targeting chimera (“PROTAC”) compound GT20029 tincture for
the treatment of male androgenetic alopecia (“AGA”) has reached the primary
endpoint, with statistically significant and clinically meaningful results, as
well as good safety and tolerability. Based on the results of the Phase II
Clinical Trial, the company will actively deploy subsequent clinical strategies
for GT20029, such as initiating a phase III clinical trial in China and a phase
II clinical trial in the U.S. for male AGA. In addition, the company is also
preparing to conduct a phase II clinical trial of GT20029 for the treatment of
acne.The Phase II Clinica
………………………………
